Information Provided By: 
Fly News Breaks for July 20, 2017
PTCT
Jul 20, 2017 | 08:58 EDT
Citi analyst Joel Beatty raised his price target for PTC Therapeutics to $28 saying he still sees "multiple paths" to U.S. approval of Translarna. He expects the stock to trade up into the FDA panel meeting on September 28. The analyst values PTC's base business at $17 per share and pipeline at $11. Beatty maintains a Buy rating on PTC.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
